Singapore markets close in 2 hours 54 minutes

Cutera, Inc. (CUTR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.5900+0.0400 (+2.58%)
At close: 04:00PM EDT
1.7800 +0.19 (+11.95%)
After hours: 07:37PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5500
Open1.5600
Bid1.5800 x 300
Ask1.6200 x 300
Day's range1.5500 - 1.8100
52-week range1.2800 - 21.4100
Volume715,543
Avg. volume619,950
Market cap32.19M
Beta (5Y monthly)1.32
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Cutera® Announces New Survey Data During Acne Awareness Month

    BRISBANE, Calif., June 13, 2024--Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announces the release of important new acne survey data as part of June’s Acne Awareness Month. The findings highlight the impact of acne on individuals and emphasize the substantial role of novel treatments like AviClear®, the first FDA-cleared energy-based device for the long-term treatment of mild, moderate, and severe inflammatory acne, in improving quality of life.

  • Business Wire

    Cutera® Appoints Jeryl L. Hilleman to Board of Directors

    BRISBANE, Calif., June 10, 2024--CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that Jeryl "Jeri" Hilleman will join its Board of Directors, effective July 12, 2024.

  • Business Wire

    Cutera® Announces AviClear® Investor Webinar

    BRISBANE, Calif., June 07, 2024--CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will hold an investor webinar at 11 a.m. PDT on June 20, 2024, to present an overview of AviClear, the first FDA-cleared energy device for the long-term treatment of mild, moderate, and severe inflammatory acne. The webinar will include a review of clinical data, market opportunity, future clinical studies, and real-world user experience.